Literature DB >> 24887231

Matching for the D antigen in haematopoietic progenitor cell transplantation: definition and clinical outcomes.

Joan Cid1, Miguel Lozano2, Harvey G Klein3, Willy A Flegel3.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24887231      PMCID： PMC4111809          DOI： 10.2450/2014.0238-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  24 in total

Review 1.  Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs.

Authors:  S D Rowley
Journal:  Bone Marrow Transplant       Date:  2001-08       Impact factor: 5.483

2.  Rh D alloimmunization in allogeneic HSCT.

Authors:  J Y S Chan; M Tokessy; E Saidenberg; A Giulivi; J Tay; D S Allan
Journal:  Bone Marrow Transplant       Date:  2012-08-13       Impact factor: 5.483

3.  Hemolysis in Rh-negative female recipient after Rh-incompatible bone marrow transplantation for chronic myeloid leukemia.

Authors:  G Girelli; W Arcese; A Bianchi; F R Mauro; F Malagnino; G Adorno; A Iurlo; M P Perrone; G Papa
Journal:  Haematologica       Date:  1986 Jan-Feb       Impact factor: 9.941

4.  Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation.

Authors:  J Hows; K Beddow; E Gordon-Smith; D R Branch; W Spruce; I Sniecinski; R A Krance; L D Petz
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

5.  Engraftment of RH-positive marrow in a recipient with RH antibody.

Authors:  E M Berkman; S N Caplan
Journal:  Transplant Proc       Date:  1977-03       Impact factor: 1.066

6.  Alloimmunization to RhD antigen in RhD-incompatible haemopoietic cell transplants with non-myeloablative conditioning.

Authors:  Aleksandar Mijovic
Journal:  Vox Sang       Date:  2002-11       Impact factor: 2.144

7.  Posttransplant immune-mediated hemolysis.

Authors:  Robert J Sokol; Robert Stamps; David J Booker; Fiona M Scott; Stuart T Laidlaw; Elisabeth A Vandenberghe; Helen F Barker
Journal:  Transfusion       Date:  2002-02       Impact factor: 3.157

8.  Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation.

Authors:  L C Lasky; P I Warkentin; J H Kersey; N K Ramsay; P B McGlave; J McCullough
Journal:  Transfusion       Date:  1983 Jul-Aug       Impact factor: 3.157

Review 9.  Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation.

Authors:  M Franchini; G Gandini; G Aprili
Journal:  Bone Marrow Transplant       Date:  2004-06       Impact factor: 5.483

10.  Transplant of rhesus-positive bone marrow in a rhesus-negative woman having anti-rhesus D alloantibodies.

Authors:  D Rigal; M Monestier; F Meyer; P J Tremisi; H Vu Van; D Fiere; A Jouvenceaux
Journal:  Acta Haematol       Date:  1985       Impact factor: 2.195
View more
  4 in total

1.  RhD and haematopoietic transplantation.

Authors:  David S Allan; Elianna Saidenberg
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

2.  Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study.

Authors:  Joan Cid; Miguel Lozano; Alyssa Ziman; Kamille A West; Kerry L O'Brien; Michael F Murphy; Silvano Wendel; Alejandro Vázquez; Xavier Ortín; Tor A Hervig; Meghan Delaney; Willy A Flegel; Mark H Yazer
Journal:  Br J Haematol       Date:  2014-10-04       Impact factor: 6.998

3.  Platelet Transfusion Induces Alloimmunization to D and Non-D Rhesus Antigens.

Authors:  Johanna Reckhaus; Markus Jutzi; Stefano Fontana; Vera Ulrike Bacher; Marco Vogt; Michael Daslakis; Behrouz Mansouri Taleghani
Journal:  Transfus Med Hemother       Date:  2018-05-24       Impact factor: 3.747

4.  Anti-D immunization rates may exceed 50% in many clinically relevant settings, despite varying widely among patient cohorts.

Authors:  Willy Albert Flegel; Franz Friedrich Wagner; Diarmaid Padraig Ó Donghaile
Journal:  Transfusion       Date:  2020-05       Impact factor: 3.157
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.